3 Mining Stocks With Earnings Growth And Balance Sheet Strength

Global markets are being pulled in different directions by inflation, interest rate expectations, and energy prices, which makes it harder to separate durable growth stories from everything else. The Healthy high growth potential screener focuses on companies where analysts expect solid earnings growth over the next 3 years and that also sit in what is assessed as an acceptable financial position. That combination can help you concentrate on businesses that are not only aiming for higher profits but are also not stretched on fundamentals. Below are 3 stocks from this screener that stand out on these criteria.

Overview: Alkane Resources is an Australian based gold exploration and production company with three operating gold and antimony mines across Australia and Sweden, alongside the large Boda Kaiser gold copper project in New South Wales. It also has exposure to copper, nickel, zinc and silver, and invests in junior gold mining companies and projects.

Market Cap: A$2.19b

Alkane Resources is attracting attention because it combines a growing multi mine gold and antimony production base with very strong recent earnings momentum and analyst forecasts that, according to the article, indicate further earnings growth of around 36.2% a year. The stock currently trades well below one estimate of fair value and on a lower P/E than many peers. This can appeal if you are looking for potential mispricing. At the same time, heavy use of external borrowing and recent shareholder dilution highlight that funding and capital allocation are important watchpoints. In addition, board independence of only 33% presents a company with clear upside drivers and notable governance and financing considerations that investors may wish to weigh carefully.

Alkane Resources looks like an earnings story that the market has not fully priced, yet heavy borrowing and dilution make the next moves critical. See how the 4 key rewards and 1 important major warning sign could reshape the whole picture.

Overview: Endeavour Mining is a London headquartered gold producer that operates a portfolio of gold mines and development projects across West Africa, with additional exposure to copper and silver through its exploration activities. Its key operations include the Houndé, Mana, Ity, Lafigué, Sabodala Massawa, Kalana, and Assafou projects in Burkina Faso, Côte d’Ivoire, Senegal, and Mali.

Operations: Endeavour Mining generates its revenue primarily from its mines at Ity (US$1.21b), Sabodala Massawa (US$1.04b), Houndé (US$843.4m), Lafigué (US$785.4m), and Mana (US$660.7m).

Market Cap: CA$18.67b

Endeavour Mining is drawing interest because it combines a multi asset West African production base with high reported profitability. This includes a current return on equity of 28.6% and analyst expectations for 21.41% annual earnings growth. At the same time, the stock is assessed as trading well below some fair value estimates and supported by an active buyback program. A recently approved Tier 1 Assafou project and continuing optimization at Sabodala Massawa point to potential volume and margin uplift. However, everything hinges on execution and gold prices, with concentrated regional exposure, working capital tied up in VAT receivables, insider selling and an unstable dividend history all reminding investors that the risk profile is real and worth monitoring closely.

High reported profitability, an active buyback, and a large West African mine portfolio make Endeavour Mining look like a valuation story the market has not fully joined. See how the 3 key rewards and 2 important warning signs might change your view.

Overview: Legend Biotech is a biopharmaceutical company that develops and commercializes cell therapies for cancer, led by its CAR-T treatment cilta-cel (marketed as CARVYKTI) for multiple myeloma, while also advancing a pipeline of earlier stage CAR-T and cell therapy candidates across blood cancers and solid tumors in the US, China, and Europe.

Operations: Legend Biotech generates all of its US$1.14b in revenue from biotechnology, with approximately US$856.9m coming from the United States, US$254m from markets outside the US, and US$28.1m from China.

Market Cap: US$5.19b

Legend Biotech stands out because CARVYKTI has become a key therapy in multiple myeloma, backed by strong clinical data and expanding global use. Early results from programs like LB2501 and LB2102 suggest the potential for a broader cell therapy franchise. Some investors focus on the company’s revenue and earnings trajectory as it works toward profitability in the next few years, and the current P/S level sits well below many US biotech peers, which can attract those looking for perceived mispricing. On the other hand, there is concentration risk in a single major product, heavy external borrowing, ongoing losses, and the need to keep raising capital, as shown by the recent public offering. How those trade offs develop over time will influence whether Legend Biotech is viewed as a fit for a high growth portfolio.

Legend Biotech’s accelerating CARVYKTI story and early pipeline hints suggest the current share price may not tell the full tale, so weigh that potential against the analyst forecasts for Legend Biotech that could reveal a crucial twist

The three stocks covered here are just a starting sample, with the full Healthy high growth potential screener surfacing 1,502 more companies that pair projected earnings growth with what is assessed as acceptable financial positions and equally compelling narratives, so you can see where your own ideas line up against a much wider field via the Healthy high growth potential screener. Use Simply Wall St to identify, filter, and analyze the specific catalysts and storylines that matter to you so you can focus on the highest conviction opportunities instead of scrolling through endless tickers.

Take Control of Your Investment Journey

If Legend Biotech or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others?

New breakouts, shifting momentum, and fresh ideas rarely stay under the radar for long. Scan these curated stock shortlists before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com